Shattuck Labs prices $75m public offering to fund DR3 programme
Shattuck Labs has priced a $75 million public offering, selling a combination of common stock and pre-funded warrants to investors as the Austin and Durham-based biotech seeks fresh capital to advance its inflammatory and immune-mediated disease pipeline.
The offering comprises 10,879,376 shares priced at $4.00 each, alongside pre-funded warrants covering a further 7,870,624 shares at $3.9999 per warrant, with an exercise price of $0.0001 per share. The warrants are exercisable immediately. Closing is expected on 11 June 2026, subject to customary conditions. The underwriters hold a 30-day option to purchase up to an additional 2,812,500 shares at the offering price, which would lift gross proceeds beyond the headline figure.
Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor are acting as joint bookrunning managers. Shattuck did not disclose in this release how it intends to allocate the proceeds between specific programmes or operational costs.
The DR3 platform
Shattuck's lead candidate, SL-325, is a DR3 antagonist antibody designed to block the DR3/TL1A pathway, which the company describes as clinically validated in inflammatory disease. The company is positioning SL-325 as a potentially first-in-class agent in this mechanism class, though it has not yet published pivotal clinical data and the "first-in-class" characterisation remains the company's own designation rather than a regulatory or independent scientific determination.
The TL1A/DR3 axis has attracted considerable industry attention in recent years. Merck and Roche both hold late-stage TL1A-targeting assets, primarily developed as anti-TL1A antibodies for conditions including ulcerative colitis and Crohn's disease, demonstrating validated commercial and clinical interest in the pathway. Shattuck's DR3 blocking approach is mechanistically distinct, aiming to interfere with ligand signalling from the receptor side rather than sequestering the ligand itself. Whether that distinction translates into a meaningful clinical or commercial advantage over the more established anti-TL1A approach remains to be demonstrated in head-to-head or large-scale data.
Market context
Public equity raises by clinical-stage biotechs have remained an important source of non-dilutive runway extension in 2025 and into 2026, even as broader market volatility has compressed valuations for many NASDAQ-listed biotechs. Shattuck's offering price of $4.00 per share reflects pricing typical of a company at this stage, and the use of pre-funded warrants alongside common stock is a structure commonly adopted when certain institutional investors face regulatory or policy constraints on holding shares directly.
The immunology and autoimmune space continues to draw investor interest, buoyed by the commercial success of biologics targeting IL-17, IL-23, and JAK pathways in conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. The DR3/TL1A mechanism adds a further dimension to this competitive landscape, and Shattuck will need to demonstrate differentiated clinical outcomes to command meaningful market positioning.
The next near-term milestone for investors will be clinical data from the SL-325 programme, alongside clarity on the indications Shattuck intends to prioritise with the newly raised capital.